200 related articles for article (PubMed ID: 25521641)
1. Cost-effectiveness and pricing of antibacterial drugs.
Verhoef TI; Morris S
Chem Biol Drug Des; 2015 Jan; 85(1):4-13. PubMed ID: 25521641
[TBL] [Abstract][Full Text] [Related]
2. Value-Based Pricing and Budget Impact Analysis for Multi-Indication Drugs: A Case Study of Immunotherapies.
Ha SY; Kang DW; Jung HI; Lee EK; Park MH
Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409788
[TBL] [Abstract][Full Text] [Related]
3. Effective antibacterials: at what cost? The economics of antibacterial resistance and its control.
White AR;
J Antimicrob Chemother; 2011 Sep; 66(9):1948-53. PubMed ID: 21700625
[TBL] [Abstract][Full Text] [Related]
4. Pharmacoeconomics of antibacterial treatment.
Davey PG; Malek MM; Parker SE
Pharmacoeconomics; 1992 Jun; 1(6):409-37. PubMed ID: 10147022
[TBL] [Abstract][Full Text] [Related]
5. The impact of pricing strategy on the costs of oral anti-cancer drugs.
Truong J; Chan KKW; Mai H; Chambers A; Sabharwal M; Trudeau ME; Cheung MC
Cancer Med; 2019 Jul; 8(8):3770-3781. PubMed ID: 31132223
[TBL] [Abstract][Full Text] [Related]
6. Convergence of decision rules for value-based pricing of new innovative drugs.
Gandjour A
Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):209-13. PubMed ID: 25327543
[TBL] [Abstract][Full Text] [Related]
7. Pharmaceutical Reference Pricing: Does It Have a Future in the U.S.?
Robinson JC
Issue Brief (Commonw Fund); 2018 Sep; 2018():1-6. PubMed ID: 30199167
[TBL] [Abstract][Full Text] [Related]
8. Implementation of Value-based Pricing for Medicines.
Jommi C; Armeni P; Costa F; Bertolani A; Otto M
Clin Ther; 2020 Jan; 42(1):15-24. PubMed ID: 31882225
[TBL] [Abstract][Full Text] [Related]
9. The development of a value based pricing index for new drugs in metastatic colorectal cancer.
Dranitsaris G; Truter I; Lubbe MS
Eur J Cancer; 2011 Jun; 47(9):1299-304. PubMed ID: 21493060
[TBL] [Abstract][Full Text] [Related]
10. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
11. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.
Luepke KH; Suda KJ; Boucher H; Russo RL; Bonney MW; Hunt TD; Mohr JF
Pharmacotherapy; 2017 Jan; 37(1):71-84. PubMed ID: 27859453
[TBL] [Abstract][Full Text] [Related]
12. Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic.
Neumann PJ; Cohen JT; Kim DD; Ollendorf DA
Health Aff (Millwood); 2021 Jan; 40(1):53-61. PubMed ID: 33211534
[TBL] [Abstract][Full Text] [Related]
13. Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures.
Danzon PM
Value Health; 2018 Mar; 21(3):252-257. PubMed ID: 29566830
[TBL] [Abstract][Full Text] [Related]
14. Can price controls reduce pharmaceutical expenses? A case study of antibacterial expenditures in 12 Chinese hospitals from 1996 to 2005.
Han S; Liang H; Su W; Xue Y; Shi L
Int J Health Serv; 2013; 43(1):91-103. PubMed ID: 23527456
[TBL] [Abstract][Full Text] [Related]
15. The Price of Progress: Cost, Access, and Adoption of Novel Cardiovascular Drugs in Clinical Practice.
Varghese MS; Liu CL; Kazi DS
Curr Cardiol Rep; 2021 Oct; 23(11):163. PubMed ID: 34599393
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness opportunities for new antibiotics.
Hillman A
Pharmacoeconomics; 1994; 5(Suppl 2):40-3. PubMed ID: 10147288
[TBL] [Abstract][Full Text] [Related]
17. The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for Brodalumab.
Brixner D; Oderda G; Biskupiak J; Burgoyne DS; Avey SG; Feldman SR
Am Health Drug Benefits; 2019 Feb; 12(1):22-26. PubMed ID: 30972150
[TBL] [Abstract][Full Text] [Related]
18. Differential pricing of drugs: a role for cost-effectiveness analysis?
Lopert R; Lang DL; Hill SR; Henry DA
Lancet; 2002 Jun; 359(9323):2105-7. PubMed ID: 12086780
[TBL] [Abstract][Full Text] [Related]
19. Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 2: Cost-effectiveness analyses.
Henry JA; Rivas CA
Pharmacoeconomics; 1997 Jun; 11(6):515-37. PubMed ID: 10168093
[TBL] [Abstract][Full Text] [Related]
20. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
Johnson JT; Neill KK; Davis DA
J Manag Care Pharm; 2011 Apr; 17(3):200-12. PubMed ID: 21434697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
